The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid β-Amyloid 42 in Adults With Normal Cognition
Abstract
BACKGROUND: Decreased cerebrospinal fluid (CSF) beta-amyloid 42 (A beta 42) concentration, but not A beta 40 concentration, is a biomarker for Alzheimer disease. This A beta 42 concentration decrease in CSF likely reflects precipitation of A beta 42 in amyloid plaques in brain parenchyma. This pathogenic plaque deposition begins years before the clinical expression of dementia in Alzheimer disease. Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease. OBJECTIVE: To estimate the interactive effects of normal aging and presence of the APOE*4 allele on CSF A beta 42 concentration in adults with normal cognition across the life span. DESIGN: The CSF was collected in the morning after an overnight fast using Sprotte 24-g atraumatic spinal needles. The CSF A beta 42 and A beta 40 concentrations were measured in the 10th milliliter of CSF collected by sandwich enzyme-linked immunosorbent assay. The APOE genotype was determined by a restriction digest method. Subjects One hundred eighty-four community volunteers with normal cognition aged 21 to 88 years. RESULTS: The CSF A beta 42, but not the A beta 40, concentration decreased significantly with age. There was a sharp decrease in CSF A beta 42 concentration beginning in the sixth decade in subjects with the APOE*4 allele. This age-associated decrease in CSF A beta 42 concentration was significantly and substantially greater in subjects with the APOE*4 allele compared with those without the APOE*4 allele. CONCLUSION: These CSF A beta 42 findings are consistent with acceleration by the APOE*4 allele of pathogenic A beta 42 brain deposition starting in later middle age in persons with normal cognition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies of non-demented individuals report that while CSF Aβ levels seem to decline during young adulthood, during late mid-life CSF Aβ levels may actually slightly increase [219, 220].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [220]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Mild cognitive impairment in the elderly: Predictors of dementia
Flicker, C., Ferris, S. H., & Reisberg, B. (1991) · Neurology · doi:10.1212/wnl.41.7.1006 · Cited by 838
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · cited 7×
“The A peptide is generated by proteolytic processing of the amyloid precursor protein into a series of fragments 38 to 42 amino acids long; A 42 represents about 10% of synthesized A but is by far the earliest and predominant A species deposited in plaques in AD.(5) Decreased concentration of A 42 in CSF is a consiste…”
BackgroundInfluentialCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 621
Cited by
Sorted by citations
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease
Gaser, C., Franke, K., Klöppel, S., Koutsouleris, N., Sauer, H., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067346 · Cited by 555
Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462
Pathological correlates of dementia in a longitudinal, population‐based sample of aging
Sonnen, J. A., Larson, E. B., Crane, P. K., Haneuse, S., Li, G., Schellenberg, G. D., Craft, S., Leverenz, J. B., & Montine, T. J. (2007) · Annals of Neurology · doi:10.1002/ana.21208 · Cited by 432
Self-citationA common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease
The International Genomics of Alzheimer's Project, Huang, K.-L., Initiative, T. A. D. N., Marcora, E., Pimenova, A. A., Di Narzo, A. F., Kapoor, M., Jin, S. C., Harari, O., Bertelsen, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4587 · Cited by 423
Self-citationLewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
van der Flier, W. M., Pijnenburg, Y. A. L., Fox, N. C., & Scheltens, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70306-9 · Cited by 321
Disease-modifying therapies for Alzheimer disease
Cummings, J. L., Doody, R. S., & Clark, C. (2007) · Neurology · doi:10.1212/01.wnl.0000295996.54210.69 · Cited by 284
Self-citationCSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 275
Self-citationShaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
Self-citationUngar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 225
Varga, A. W., Wohlleber, M. E., Giménez, S., Romero, S., Alonso, J. F., Ducca, E. L., Kam, K., Lewis, C., Tanzi, E. B., Tweardy, S., et al. (2016) · SLEEP · doi:10.5665/sleep.6240 · Cited by 203
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M. J., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160907 · Cited by 211
Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment
Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., Pickering, E. H., Kühn, M., Chen, Y., McCluskey, L. F., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0667-0 · Cited by 196
Self-citationDiniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 173
Ibáñez, C., Simó, C., Martín‐Álvarez, P. J., Kivipelto, M., Winblad, B. G., Cedazo-Mı́nguez, Á., & Cifuentes, A. (2012) · Analytical Chemistry · doi:10.1021/ac301243k · Cited by 168
Age and diagnostic performance of Alzheimer disease CSF biomarkers
Mattsson, N., Rosén, E., Hansson, O., Andreasen, N. C., Parnetti, L., Jonsson, M. A. G., Herukka, S., van der Flier, W. M., Blankenstein, M. A., Ewers, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182477eed · Cited by 172
APOE modifies the association between Aβ load and cognition in cognitively normal older adults
Kantarci, K., Lowe, V. J., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., Preboske, G. M., Roberts, R. O., Geda, Y. E., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31824365ab · Cited by 168
Cedazo-Mínguez, Á., & Winblad, B. G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.09.008 · Cited by 159
Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment
Bayer-Carter, J. L., Green, P. S., Montine, T. J., VanFossen, B. T., Baker, L. D., Watson, G. S., Bonner, L. M., Callaghan, M., Leverenz, J. B., Walter, B. K., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.125 · Cited by 160
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Ushering in the study and treatment of preclinical Alzheimer disease
Langbaum, J. B. S., Fleisher, A., Chen, K., Ayutyanont, N., Lopera, F. J., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 149
CSF biomarker levels in early and late onset Alzheimer's disease
Bouwman, F. H., Schoonenboom, N. S. M., Verwey, N. A., van Elk, E. J., Kok, A., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.007 · Cited by 150
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136
MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer’s Disease
Lusardi, T. A., Phillips, J. I., Wiedrick, J. T., Harrington, C. A., Lind, B., Lapidus, J., Quinn, J. F., & Saugstad, J. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160835 · Cited by 135
Self-citationOsorio, R. S., Ayappa, I. A., Mantua, J., Gumb, T., Varga, A. W., Mooney, A. M., Burschtin, O. E., Taxin, Z. H., During, E., Spector, N. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.030 · Cited by 127
Giedraitis, V., Sundelöf, J. E., Irizarry, M. C., Gårevik, N., Hyman, B. T., Wahlund, L., Ingelsson, M., & Lannfelt, L. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.023 · Cited by 127
Chiu, C., Miller, M. C., Caralopoulos, I. N., Worden, M. S., Brinker, T., Gordon, Z. N., Johanson, C. E., & Silverberg, G. D. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-3 · Cited by 116
Reduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma
Bekris, L. M., Lutz, F., Montine, T. J., Yu, C. E., Tsuang, D., Peskind, E. R., & Leverenz, J. B. (2013) · Biomarkers · doi:10.3109/1354750x.2013.814073 · Cited by 97
Self-citationAge‐Varying Association Between Statin Use and Incident Alzheimer's Disease
Li, G., Shofer, J. B., Rhew, I. C., Kukull, W. A., Peskind, E. R., McCormick, W. C., Bowen, J. D., Schellenberg, G. D., Crane, P. K., Breitner, J. C. S., et al. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02906.x · Cited by 113
Self-citationPulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults
Nation, D. A., Edland, S. D., Bondi, M. W., Salmon, D. P., Delano‐Wood, L., Peskind, E. R., Quinn, J. F., & Galasko, D. R. (2013) · Neurology · doi:10.1212/01.wnl.0000436935.47657.78 · Cited by 106
Self-citationA Blood Gene Expression Marker of Early Alzheimer's Disease
Lunnon, K., Sattlecker, M., Furney, S. J., Coppola, G., Simmons, A., Proitsi, P., Lupton, M. K., Lourdusamy, A., Johnston, C., Soininen, H. S., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121363 · Cited by 104
Lacour, A., Espinosa, A., Louwersheimer, E., Heilmann, S., Hernández, I., Wolfsgruber, S., Fernández, V, Wagner, H., Rosende-Roca, M., Mauleón, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.18 · Cited by 101
Preclinical Evidence of Alzheimer Changes
Petrie, E. C., Cross, D. J., Galasko, D. R., Schellenberg, G. D., Raskind, M. A., Peskind, E. R., & Minoshima, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.59 · Cited by 102
Self-citationLeoni, V. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.088 · Cited by 102
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic
Duits, F. H., Prins, N. D., Lemstra, A. W., Pijnenburg, Y. A. L., Bouwman, F. H., Teunissen, C. E., Scheltens, P., & van der Flier, W. M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1753 · Cited by 98
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
Mistur, R. L., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 101
Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles
Bennett, D. A., De Jager, P. L., Leurgans, S. E., & Schneider, J. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e87d · Cited by 93
Głodzik-Sobańska, L., Pirraglia, E., Bryś, M., Santi, S. D., Mosconi, L., Rich, K. E., Switalski, R., Louis, L. S., Sadowski, M. J., Martiniuk, F. T., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.019 · Cited by 92
Bekris, L. M., Millard, S. P., Galloway, N. M., Vuletic, S., Albers, J. J., Li, G., Galasko, D. R., DeCarli, C., Farlow, M. R., Clark, C. M., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13303 · Cited by 85
Self-citationKauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84
Biomarkers for cognitive impairment and dementia in elderly people
Sonnen, J. A., Montine, K. S., Quinn, J. F., Kaye, J. A., Breitner, J. C. S., & Montine, T. J. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70162-5 · Cited by 78
Self-citationOxidative stress in Alzheimer's disease: Primary villain or physiological by-product?
Sutherland, G. T., Chami, B., Youssef, P., & Witting, P. K. (2013) · Redox Report · doi:10.1179/1351000213y.0000000052 · Cited by 80
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 72
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts
Resnick, S. M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M., Thambisetty, M., Prince, J. L., Zhou, Y., Soldan, A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.001 · Cited by 65
Christensen, H. M., Batterham, P. J., Mackinnon, A. J., Jorm, A. F., Mack, H. A., Mather, K. A., Anstey, K. J., Sachdev, P. S., & Easteal, S. (2008) · BMC Geriatrics · doi:10.1186/1471-2318-8-14 · Cited by 64
Mattsson, N., Insel, P. S., Nosheny, R. L., Zetterberg, H., Trojanowski, J. Q., Shaw, L. M. J., Tosun, D., Weiner, M. W., & Initiative, A. D. N. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.69 · Cited by 62
Differential effects of the ApoE4 genotype on brain structure and function
Matura, S., Prvulovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., O’Dwyer, L., Oertel‐Knöchel, V., Knöchel, C., Reinke, B., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.042 · Cited by 63
Liu, J., Kiehl, K. A., Pearlson, G. D., Perrone‐Bizzozero, N. I., Eichele, T., & Calhoun, V. D. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.045 · Cited by 62
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. J. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 63
Baker, L. D., Bayer-Carter, J. L., Skinner, J. S., Montine, T. J., Cholerton, B., Callaghan, M., Leverenz, J. B., Walter, B. K., Tsai, E. C., Postupna, N. O., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111076 · Cited by 54
Li, G., Shofer, J. B., Petrie, E. C., Yu, C., Wilkinson, C. W., Figlewicz, D. P., Shutes‐David, A., Zhang, J., Montine, T. J., Raskind, M. A., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0271-9 · Cited by 53
Self-citationBekris, L. M., Galloway, N. M., Millard, S. P., Lockhart, D., Li, G., Galasko, D. R., Farlow, M. R., Clark, C. M., Quinn, J. F., Kaye, J. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.020 · Cited by 53
Self-citationKester, M. I., Blankenstein, M. A., Bouwman, F. H., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0999 · Cited by 50
The development of effective biomarkers for Alzheimer's disease: a review
Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3829 · Cited by 51
Basak, J. M., Ferreiro, A., Cohen, L. S., Sheehan, P. W., Nadarajah, C. J., Kanan, M. F., Sukhum, K. V., Dantas, G., & Musiek, E. S. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105292 · Cited by 46
Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease
Shulman, J. M., Chibnik, L. B., Aubin, C., Schneider, J. A., Bennett, D., & Jager, P. L. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011244 · Cited by 47
Sun, X., Chiu, C. C., Liebson, E. S., Crivello, N. A., Wang, L., Claunch, J. D., Folstein, M. F., Rosenberg, I. H., Mwamburi, D. M., Peter, I., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819cb3ac · Cited by 46
Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults
Fan, M., Liu, B., Zhou, Y., Zhen, X., Xu, C., & Jiang, T. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.05.092 · Cited by 43
The Alzheimer Myth and Biomarker Research in Dementia
Richard, E., Schmand, B. A., Eikelenboom, P., Westendorp, R. G. J., & van Gool, W. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112216 · Cited by 42
Frisardi, V., Panza, F., & Farooqui, A. A. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.04.003 · Cited by 42
CSF beta‐amyloid 1–42 – what are we measuring in Alzheimer's disease?
Hu, W. T., Watts, K. D., Shaw, L. M. J., Howell, J. C., Trojanowski, J. Q., Basra, S. S., Glass, J. D., Lah, J. J., & Levey, A. I. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.160 · Cited by 38
Pan, C., Korff, A., Galasko, D. R., Ginghină, C., Peskind, E. R., Li, G., Quinn, J. F., Montine, T. J., Cain, K. C., Shi, M. Y., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143099 · Cited by 36
Self-citationFeinkohl, I., Schipke, C. G., Kruppa, J., Menne, F., Winterer, G., Pischon, T., & Peters, O. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200046 · Cited by 38
Popp, J., Lewczuk, P., Frommann, I., Kölsch, H., Kornhuber, J., Maier, W., & Jessen, F. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100561 · Cited by 36
Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span
Wang, L. Y., Murphy, R. R., Hanscom, B. S., Li, G., Millard, S. P., Petrie, E. C., Galasko, D. R., Sikkema, C. L., Raskind, M. A., Wilkinson, C. W., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.007 · Cited by 35
Self-citationMeasurement of Aβ1–42 in cerebrospinal fluid is influenced by matrix effects
Slemmon, J. R., Meredith, J. E., Guss, V. L., Andréasson, U., Andreasen, N., Zetterberg, H., & Blennow, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07553.x · Cited by 36
Paternicò, D., Galluzzi, S., Drago, V., Bocchio‐Chiavetto, L., Zanardini, R., Pedrini, L., Baronio, M., Amicucci, G., & Frisoni, G. B. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.10.003 · Cited by 34
Bouter, C., Vogelgsang, J. S., & Wiltfang, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.005 · Cited by 32
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
ADAM10 expression and promoter haplotype in Alzheimer's disease
Bekris, L. M., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., Montine, T. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.013 · Cited by 31
Self-citationCerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
Park, S. A., Chae, W. S., Kim, H. J., Shin, H. S., Kim, S., Im, J. Y., Ahn, S. I., Min, K. D., Yim, S. J., Ye, B. S., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000184 · Cited by 28
Stewart, T., Initiative, A. F. T. A. D. N., Shi, M. Y., Mehrotra, A., Aro, P., Soltys, D., Kerr, K. F., Zabetian, C. P., Peskind, E. R., Taylor, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190069 · Cited by 24
Self-citationGeerts, H., Walker, M., Rose, R., Bergeler, S., van der Graaf, P. H., Schuck, E. L., Koyama, A., Yasuda, S., Hussein, Z., Reyderman, L., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12912 · Cited by 24
Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia
Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. S., & Montine, T. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1236 · Cited by 24
Self-citationCerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 25
Cerebrospinal fluid Aβ 42 levels and APP processing pathway genes in Parkinson's disease
Bekris, L. M., Tsuang, D. W., Peskind, E. R., Yu, C., Montine, T. J., Zhang, J., Zabetian, C. P., & Leverenz, J. B. (2015) · Movement Disorders · doi:10.1002/mds.26172 · Cited by 22
Self-citationTau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease
Bekris, L. M., Millard, S., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., et al. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32094 · Cited by 20
Self-citationSlemmon, J. R., Shapiro, A., Mercken, M. H., Streffer, J. R., Romano, G. J., Andreasen, N., Zetterberg, H., & Blennow, K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13297 · Cited by 20
ABCB1 Genotype and CSF β-Amyloid in Alzheimer Disease
Kohen, R., Shofer, J. B., Korvatska, O., Petrie, E. C., Wang, L. Y., Schellenberg, G. D., Peskind, E. R., & Wilkinson, C. W. (2011) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988711402325 · Cited by 16
Self-citationCSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury
Li, G., Iliff, J. J., Shofer, J. B., Mayer, C. L., Meabon, J. S., Cook, D. G., Pagulayan, K. F., Raskind, M. A., Zetterberg, H., Blennow, K., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209197 · Cited by 14
Self-citationBiomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Dupiereux-Fettweis, I., Zorzi, W., Quadrio, I., Perret‐Liaudet, A., Kovács, G. G., Heinen, E., & Elmoualij, B. (2009) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152409787601950 · Cited by 16
van der Spoel, E., van Vliet, N. A., & van Heemst, D. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100964 · Cited by 11
Stenset, V. T. V., Hofoss, D., Johnsen, L., Berstad, A. E., Negaard, A., Skinningsrud, A., Gjerstad, L., & Fladby, T. (2009) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2009.00444.x · Cited by 10
Laboratory biomarkers in Alzheimer’s disease
Steinerman, J. R., & Honig, L. S. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0059-6 · Cited by 9
Haapalinna, F., Kokki, M., Jääskeläinen, O., Hallikainen, M., Helisalmi, S., Koivisto, A. M., Kokki, H. J., Paajanen, T. I., Penttinen, J., Pikkarainen, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170534 · Cited by 9
Geerts, H., Bergeler, S., Lytton, W., & van der Graaf, P. H. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09876-6 · Cited by 7
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects
Millard, S. P., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., Yu, C., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.027 · Cited by 8
Self-citationA Common Haplotype Lowers PU.1 Expression in Myeloid Cells and Delays Onset of Alzheimer's Disease
Huang, K.-L., Marcora, E., Pimenova, A. A., Di Narzo, A. F., Kapoor, M., Jin, S. C., Harari, O., Bertelsen, S., Fairfax, B. P., Czajkowski, J., et al. (2017) · doi:10.1101/110957 · Cited by 6
Self-citation
Metadata
- Authors
- Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C., Raskind, M. A., Schellenberg, G. D., Lee, V. M.-Y., & Galasko, D. R.
- Affiliations
- University of Washington (US)
- Oregon Health & Science University (US)
- University of Pennsylvania (US)
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
- University of California San Diego (US)
- ORCID
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 936
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2104954974
- Cited by
- 131
- References
- 20
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 14 · 2012: 17
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag008419-15)
- National Institute on Aging (AG 10133, P30AG010133, AG08419, AG 08017, AG23185, AG 05136, P30AG010124, P30AG008017, AG-10124, R01AG023185, P50AG005136)
- National Center for Research Resources (M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Aβ40, normal aging, Alzheimer's disease risk, cerebrospinal fluid biomarkers, normal cognition
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Alleles, Apolipoproteins E, Brain, Cognition, Female, Genotype, Humans, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
